PROCEPT BioRobotics (NASDAQ:PRCT) Sets New 52-Week Low – Should You Sell?

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) reached a new 52-week low on Friday . The stock traded as low as $29.50 and last traded at $29.97, with a volume of 251526 shares changing hands. The stock had previously closed at $30.42.

Wall Street Analysts Forecast Growth

PRCT has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Wednesday, October 8th. Truist Financial lowered their price objective on PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, October 15th. Leerink Partners reaffirmed an “outperform” rating and issued a $55.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. Wells Fargo & Company dropped their target price on shares of PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Finally, Oppenheimer upgraded PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 target price for the company in a report on Tuesday, September 2nd. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $59.78.

PROCEPT BioRobotics Price Performance

The stock’s 50-day moving average is $35.37 and its 200 day moving average is $47.04. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.20 and a current ratio of 8.44. The stock has a market capitalization of $1.67 billion, a PE ratio of -19.57 and a beta of 0.98.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.03. The company had revenue of $83.33 million for the quarter, compared to analyst estimates of $80.78 million. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.The firm’s revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.40) earnings per share. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts expect that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On PROCEPT BioRobotics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Thematics Asset Management increased its holdings in shares of PROCEPT BioRobotics by 59.6% in the 3rd quarter. Thematics Asset Management now owns 630,053 shares of the company’s stock valued at $22,487,000 after purchasing an additional 235,344 shares in the last quarter. Prosight Management LP purchased a new stake in PROCEPT BioRobotics during the third quarter worth about $2,748,000. Comerica Bank grew its position in PROCEPT BioRobotics by 4.8% during the third quarter. Comerica Bank now owns 386,416 shares of the company’s stock worth $13,791,000 after buying an additional 17,832 shares during the period. Marshall Wace LLP increased its holdings in PROCEPT BioRobotics by 9,100.2% in the third quarter. Marshall Wace LLP now owns 381,534 shares of the company’s stock valued at $13,617,000 after buying an additional 377,387 shares in the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in PROCEPT BioRobotics in the third quarter valued at about $788,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).